Abstract | PURPOSE: BRCA1 and BRCA2 proteins are central to DNA repair process through homologous recombination. We hypothesize that BRCA1/BRCA2 mutation carriers may exhibit increased hematological toxicity when receiving genotoxic chemotherapy. METHODS: RESULTS: Overall, 221 patients were assessed for acute hematological toxicity, including 23 BRCA1 and 22 BRCA2 carriers. Following the C1, febrile neutropenia had an incidence of 35% (p = 0.002), 14% (p = 0.562) and 10% among BRCA1, BRCA2 and non-carriers, respectively. Grade 4 neutropenia was found in 57% of BRCA1 (p < 0.001), 14% of BRCA2 (p = 0.861) and 18% of non-carriers. G-CSF support was necessary in 86% of BRCA1 (p = 0.005), 64% of BRCA2 (p = 0.285) and 51% of non-carriers. For long-term toxicity analysis, 898 patients were included (167 BRCA1-, 91 BRCA2- and 640 non-carriers). There was no difference between the 3 groups. CONCLUSIONS: BRCA1 germline mutations is associated with greater acute hematological toxicity in breast cancer patients. These observations could have implication for primary prophylaxis with G-CSF.
|
Authors | Alex Friedlaender, Aurélie Vuilleumier, Valeria Viassolo, Aurélie Ayme, Solène De Talhouet, Jean-Damien Combes, Julien Peron, Alexandre Bodmer, Sophie Giraud, Adrien Buisson, Valerie Bonadona, Isabelle Gauchat-Bouchardy, Olivier Tredan, Pierre O Chappuis, S Intidhar Labidi-Galy |
Journal | Breast cancer research and treatment
(Breast Cancer Res Treat)
Vol. 174
Issue 3
Pg. 775-783
(Apr 2019)
ISSN: 1573-7217 [Electronic] Netherlands |
PMID | 30635808
(Publication Type: Journal Article)
|
Chemical References |
- BRCA1 Protein
- BRCA1 protein, human
- BRCA2 Protein
- BRCA2 protein, human
- Granulocyte Colony-Stimulating Factor
|
Topics |
- Adult
- BRCA1 Protein
(genetics)
- BRCA2 Protein
(genetics)
- Breast Neoplasms
(drug therapy, genetics)
- Chemotherapy, Adjuvant
(adverse effects)
- Cohort Studies
- Febrile Neutropenia
(chemically induced, epidemiology)
- Female
- France
- Germ-Line Mutation
- Granulocyte Colony-Stimulating Factor
(administration & dosage)
- Hospitalization
(statistics & numerical data)
- Humans
- Middle Aged
- Switzerland
|